Craig A. Erickson, MD
- Associate Professor, UC Department of Psychiatry and Behavioral Neuroscience
- Board Certified
About
Biography
Dr. Erickson has worked to obtain continuous federal, foundation, internal, and industry funding supporting his and his collaborators' research over the last 10 ten years of his career. He is the inventor or co-inventor on many patents focused on translational treatment development in neurodevelopmental disorders that are held at Cincinnati Children's Hospital Medical Center and at his previous employer the Indiana University School of Medicine. He is considered an international expert in the clinical treatment of fragile X syndrome and has similar expertise in fragile X-specific clinical trial development. Dr. Erickson is additionally an avid teacher of future generations of child psychiatrists has received several teaching awards for his work in physician education. He also enjoys mentoring junior faculty in the behavioral and developmental neuropsychiatry sub-field of child psychiatry.
Specifically in research, he and his colleagues have moved forward several repurposed molecules for study in fragile X syndrome and autism spectrum disorder including work with acamprosate, riluzole, ketamine, D cycloserine, and N acetyl cysteine among other repurposed molecules. He also is working now to move several novel molecules into autism and fragile X-specific study using proprietary compounds abandoned from initially intended use that may hold promise in the disorders which he and his colleagues study.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2003
MS: Indiana University School of Medicine, Indianapolis, IN, 2008
Residency: Indiana University School of Medicine, Indianapolis, IN, 2008
Fellowship: Indiana University School of Medicine, Indianapolis, IN, 2008
Certifications: Child and Adolescent Psychiatry, 2009; Adult Psychiatry, 2008
Interests
Fragile X syndrome; inpatient neurodevelopmental disorders acute crisis stabilization
Interests
Fragile X syndrome; autism spectrum disorders; neurodevelopmental disorders; molecular blood markers; quantitative measurement of pathophysiology in developmental disabilities; translational treatment development; psychiatric services for those with developmental disabilities and severe behavior
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Gaboxadol increases resting theta and alpha power without affecting evoked responses in fragile X syndrome in a home-based setting. Journal of Neurodevelopmental Disorders. 2026.
Clinical Relevance of NIH Toolbox Cognition Battery Developmental Change in Intellectual and Developmental Disabilities: Associations with Verbal Reasoning. American Journal on Intellectual and Developmental Disabilities. 2026; ahead-of-print(ahead-of-print):1-7.
Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability. Journal of Autism and Developmental Disorders. 2026; 56(5):2077-2083.
Elevated gamma spectral event peak power during auditory chirp is associated with neuropsychiatric features in Fragile X syndrome. Clinical Neurophysiology. 2026; 185:2111713.
SPG601-associated modulation of resting-state EEG and improvement in executive function in a fragile X syndrome randomized controlled crossover study. Scientific Reports. 2026; 16(1).
Parent-Reported Outcome Measures for Individuals with Fragile X Syndrome: Clinically Meaningful Change Thresholds. Journal of Autism and Developmental Disorders. 2026; 56(4):1658-1670.
Acute and chronic dosing of the GABA A alpha 2,3 selective agonist BAER-101 do not alter behavior but may impact auditory-evoked EEG responses in adults with fragile X syndrome. Scientific Reports. 2026; 16(1).
Adapting a Behavioral Intervention for Caregivers of Children with Down Syndrome or Fragile X Syndrome: A Pilot Study of RUBI-DD. Behavioral Sciences. 2026; 16(3).
A human electrophysiological signature of Fragile X pathophysiology is shared in V1 of Fmr1-/y mice. Nature Communications. 2026; 17(1):1497.
Early positive signals of cognitive outcomes in mild to moderate Alzheimer patients treated with the synaptic regenerative small molecule, SPG302. Alzheimer's and Dementia. 2025; 21(Suppl 7):e109023.
From the Blog
Positive Clinical Trial Results for a New Fragile X Treatment
Craig A. Erickson, MD2/11/2025
Exploring How Thalamocortical Modulation Impacts Brain Function in Fragile X Syndrome
Craig A. Erickson, MD, Ernest Pedapati, MD, MS, FAAP5/11/2022
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey